XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.56M
Enterprise Value$363.24K
Total Cash (Recent Filing)$250.45K
Total Debt (Recent Filing)$15.07K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,730,565
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.97
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt materially reduces financial risk and interest burden, giving the company flexibility to prioritize R&D and clinical programs. This structural balance sheet strength improves ability to withstand trial timing variability and pursue partnerships without urgent refinancing.
Narrowing Operating LossesA large reduction in operating losses versus prior years signals improving cost discipline or program optimization. Sustained narrowing of losses enhances runway prospects, lowers near-term financing needs, and strengthens the firm's ability to advance clinical milestones or negotiate favorable partner deals.
Focused Therapeutic PipelineA clear, specialized focus on kidney disease and uric-acid mechanisms creates a coherent R&D strategy and potential competitive niche. This concentration can attract targeted partnerships and expertise, improving chances of durable clinical and commercial positioning if programs progress.
Bears Say
No Revenue And Persistent Cash BurnSustained negative operating and free cash flow with no revenue requires ongoing external financing. Over the next several months this structural cash burn increases the likelihood of dilutive capital raises, pressures strategic optionality, and complicates long-term funding of clinical programs.
Shrinking Equity BaseA materially reduced equity cushion limits the firm's ability to absorb setbacks and reduces negotiating leverage with partners or lenders. This persistent erosion raises sensitivity to adverse events and raises the structural cost and frequency of future capital raises.
Very Small Internal TeamAn extremely small headcount suggests limited internal capacity to manage trials, regulatory work, and business development concurrently. Dependence on external CROs and partners increases execution risk and potential delays, a structural constraint on program delivery and scalability.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.56M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 41 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,730,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Ownership Overview
7.33%
Insiders
0.87% Other Institutional Investors
91.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---